ATE532523T1 - Zoledronsäure zur prävention oder verminderung von sekundärfrakturen nach hüftfraktur - Google Patents

Zoledronsäure zur prävention oder verminderung von sekundärfrakturen nach hüftfraktur

Info

Publication number
ATE532523T1
ATE532523T1 AT03750546T AT03750546T ATE532523T1 AT E532523 T1 ATE532523 T1 AT E532523T1 AT 03750546 T AT03750546 T AT 03750546T AT 03750546 T AT03750546 T AT 03750546T AT E532523 T1 ATE532523 T1 AT E532523T1
Authority
AT
Austria
Prior art keywords
prevent
hip fracture
zoledronic acid
reduce secondary
secondary fractures
Prior art date
Application number
AT03750546T
Other languages
English (en)
Inventor
Kenneth Lyles
Zebulun Horowitz
Original Assignee
Novartis Pharma Gmbh
Lyles Kenneth W
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31994241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE532523(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh, Lyles Kenneth W filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE532523T1 publication Critical patent/ATE532523T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
AT03750546T 2002-09-16 2003-09-15 Zoledronsäure zur prävention oder verminderung von sekundärfrakturen nach hüftfraktur ATE532523T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41106702P 2002-09-16 2002-09-16
PCT/EP2003/010239 WO2004024166A1 (en) 2002-09-16 2003-09-15 Method for preventing or reducing secondary fractures after hip fracture

Publications (1)

Publication Number Publication Date
ATE532523T1 true ATE532523T1 (de) 2011-11-15

Family

ID=31994241

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03750546T ATE532523T1 (de) 2002-09-16 2003-09-15 Zoledronsäure zur prävention oder verminderung von sekundärfrakturen nach hüftfraktur

Country Status (13)

Country Link
US (2) US20050272707A1 (de)
EP (1) EP1542700B1 (de)
JP (1) JP2006500402A (de)
CN (1) CN1681516A (de)
AT (1) ATE532523T1 (de)
AU (1) AU2003270196A1 (de)
BR (1) BR0314362A (de)
CA (1) CA2497353C (de)
ES (1) ES2376425T3 (de)
HK (1) HK1079431A1 (de)
PT (1) PT1542700E (de)
TW (1) TWI344367B (de)
WO (1) WO2004024166A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0418756A (pt) * 2004-05-19 2007-09-11 Merck & Co Inc composições e métodos para inibir a reabsorção óssea
US8071574B2 (en) 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
EP1972341A1 (de) * 2007-03-23 2008-09-24 Novartis AG Bisphosphonate und Vitamin D enthaltende Pharmazeutische Zusammensetzungen
US20110034418A1 (en) * 2008-04-04 2011-02-10 Karen Beltz Pharmaceutical composition with bisphosphonate
EP2473172B1 (de) * 2009-09-01 2015-04-08 Duke University Bisphosphonatzusammensetzungen und verfahren zur behandlung von herzfehlern
WO2013074587A1 (en) 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction
RU2542425C1 (ru) * 2013-09-23 2015-02-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в костной ткани при экспериментальном остеопорозе и переломах на его фоне комбинацией l-аргинина и лозартана
RU2540927C1 (ru) * 2013-09-23 2015-02-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в костной ткани при экспериментальном остеопорозе и переломах на его фоне комбинацией l-норвалина и розувастатина
RU2538612C1 (ru) * 2013-09-23 2015-01-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в костной ткани при экспериментальном остеопорозе и переломах на его фоне розувастатином
RU2542424C1 (ru) * 2013-09-23 2015-02-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в костной ткани при экспериментальном остеопорозе и переломах на его фоне комбинацией l-аргинина и эналаприла
RU2540926C1 (ru) * 2013-09-23 2015-02-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в костной ткани при экспериментальном остеопорозе и переломах на его фоне l-норвалином
PT3246032T (pt) * 2016-05-20 2021-10-18 Christoph Karl Composições farmacêuticas com ácido zoledrónico, cálcio e vitamina d adequadas para tratamento e/ou profilaxia de doenças do metabolismo ósseo e de efeitos secundários relacionados com terapia, como hipocalcemias

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275821B1 (de) * 1986-11-21 1992-02-26 Ciba-Geigy Ag Neue substituierte Alkandiphosphonsäuren
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
GB0012209D0 (en) * 2000-05-19 2000-07-12 Novartis Ag Organic compounds
DK1296689T3 (da) * 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater

Also Published As

Publication number Publication date
CA2497353C (en) 2012-08-28
WO2004024166A1 (en) 2004-03-25
TWI344367B (en) 2011-07-01
CA2497353A1 (en) 2004-03-25
JP2006500402A (ja) 2006-01-05
US20080193564A1 (en) 2008-08-14
BR0314362A (pt) 2005-07-19
TW200412979A (en) 2004-08-01
ES2376425T3 (es) 2012-03-13
HK1079431A1 (en) 2006-04-07
CN1681516A (zh) 2005-10-12
PT1542700E (pt) 2012-02-01
US20050272707A1 (en) 2005-12-08
EP1542700A1 (de) 2005-06-22
AU2003270196A1 (en) 2004-04-30
EP1542700B1 (de) 2011-11-09

Similar Documents

Publication Publication Date Title
HK1079431A1 (en) Zoledronic acid for preventing or reducing secondary fractures after hip fracture
ATE460893T1 (de) Orthopädische platten- und knochenschraubenanordnung
BR9909445A (pt) Método para aumentar a rigidez e resistência óssea e reduzir fraturas
CA2495110A1 (en) Method and apparatus for repairing the mid-foot region via an intramedullary nail
ATE295734T1 (de) Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums
WO2007120539A3 (en) Orthopedic device
DK0881908T3 (da) Anvendelse af fiberblastvækstfaktorer til stimulering af knoglevækst
NO20060498L (no) Metode for a promotere benvekst
TW200638946A (en) Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
DE60233803D1 (de) 5-cnac zur oralen verabreichung von parathormonfragmenten
ATE275580T1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren
EA201001097A1 (ru) Фармацевтическая композиция для профилактики и лечения резорбции костной ткани различной этиологии
MD37Z (ro) Metodă de tratament al pseudartrozei
WO2006123279A3 (en) Natural drugs containing calcium and phosphate and apparatus for iontophoretic treatment of osteoporosis
RU2010114106A (ru) Способ лечения перелома проксимального отдела плеча при тяжелой форме остеопороза
Perez Alendronic acid
UA34163A (uk) Спосіб стимулювання остеогенезу при хірургічних втручаннях на кістках щелепи
UA90745C2 (ru) Способ лечения чрез- и межвертельных переломов бедра у больных преклонного и старческого возраста
Moya-Angeler Alendronic acid/ibandronic acid/pantoprazole
Lu et al. Subtrochanteric fracture non-union with implant failure managed with exchange intramedullary nail with autogenous bone graft and supplement of bone morphogenic protein
Suresh et al. Positive effect of strontium ranelate in complex non-union femur fracture
UA36326A (uk) Пристрій для черезкісткового остеосинтезу поєднаних переломів таранної та п'яткової кісток
Giannotti Alendronic acid
王延平 Effect of repair of cranial deficiency on psychology of patients
Lee Alendronic acid/risedronic acid